Oral GLP-1 Receptor Antagonist Reduces CV Risk

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established atherosclerotic disease, CKD, or both.
Medscape Medical News

source https://www.medscape.com/viewarticle/oral-glp-1-receptor-antagonist-reduces-cv-risk-2025a10007kr?src=rss